Quarterly ResultMay 12, 2026, 04:07 PM
Curis Q1 Net Loss $24.2M; Cash $15.0M; Business Update
AI Summary
Curis, Inc. reported a net loss of $24.2 million, or $1.25 per share, for the first quarter of 2026, a significant increase from $10.6 million in Q1 2025, with no revenues due to the prior sale of Erivedge® royalties. The company provided business updates on its emavusertib clinical programs, including ongoing enrollment in the TakeAim Lymphoma trial for PCNSL and the recently initiated TakeAim CLL trial. Curis also announced upcoming milestones for clinical data and stated that its cash and cash equivalents of $15.0 million, combined with anticipated proceeds from warrant exercises, should fund operations into the second half of 2027.
Key Highlights
- Net loss for Q1 2026 was $24.2 million, compared to $10.6 million in Q1 2025.
- No revenues were reported for Q1 2026 due to the sale of Erivedge® royalties in Q4 2025.
- Research and development expenses decreased to $6.4 million in Q1 2026 from $8.5 million in Q1 2025.
- General and administrative expenses increased to $5.1 million in Q1 2026 from $4.0 million in Q1 2025.
- Cash and cash equivalents totaled $15.0 million as of March 31, 2026.
- Company expects to announce dosing of initial 5 patients in TakeAim CLL study by mid-2026, with data in December 2026.
- Updated emavusertib clinical data from TakeAim Lymphoma study in R/R PCNSL is expected in H1 2027.
- Cash runway, including anticipated warrant exercise, is projected into the second half of 2027.